Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis

The Lancet

Volumn 339, Issue 8787, 1992, Pages 200-205

  MacLennan, I C M ^a   Chapman, C ^a   Dunn, J ^a   Kelly, K ^a   For The Medical Research Council Working Party For Leukaemia In Adults ^b  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b CRC Trials Unit University of Birmingham Medical School ^*

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; MELPHALAN; PREDNISONE; VINCRISTINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA 2-MICROGLOBULIN; CARMUSTINE; CAUSE OF DEATH; COMPARATIVE STUDY; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMAN; MELPHALAN; MULTIPLE MYELOMA; PROGNOSIS; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS;

EID: 0026557313     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/0140-6736(92)90004-M     Document Type: Article

References (23)

1. The survival time of patients with plasmacytic myeloma
2. Myelomatosis: comparison of melphalan and cyclophosphamide therapy
3. Report on the second myelomatosis trial after five years of follow-up
4. Improved survival duration with combination chemotherapy induction for multiple myeloma: a southwest oncology group study
5. Chemotherapy of myeloma: drug combinations versus single agents, an overview and comments on acute leukaemia in myeloma
6. Multiple myeloma treated with high dose intravenous melphalan
7. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors
8. Doxorubicin/BCNU chemotherapy for multiple myeloma in relapse
9. Results of the MRC myelomatosis trials for patients entered since 1980
10. Treatment of advanced plasma cell myeloma with weekly cyclophosphamide and alternate-day prednisone
11. Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis
12. 2-microglobulin compared with other presentation features in myelomatosis
13. Design and analysis of randomized clinical trials requiring prolonged observation of each patient I. Introduction and design
14. Design and analysis of randomized clinical trials requiring prolonged observation of each patient II. Analysis and example
15. Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a southwest oncology group study
16. Multiple myeloma: VMCP/VBAP alternating chemotherapy is not superior to melphalan and prednisone even in high risk patients
17. A randomised multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma
18. Initial treatment in multiple myeloma: no advantage of multi-drug chemotherapy over melphalanprednisolone
19. Prognostic features in the third MRC myelomatosis trial
20. Prognostic factors and staging system for multiple myeloma: comparisons between the MRC studies in the United Kingdom and the southwest oncology group studies in the United States
21. Allogeneic bone marrow transplantation in patients with multiple myeloma
22. A clinical staging system for multiple myeloma